All Activity

If anyone is trying to estimate when they'll reach Coast FIRE Calculator, this free calculator makes the process much easier than doing the maths manually:

A Leading Center of Academic Excellence in Iraq The University of AlMaarif (UOA) is one of Iraq's distinguished private universities, located in the city of Ramadi, the capital of Al Anbar Governorate. Established in 1993 and officially recognized by the Iraqi Ministry of Higher Education and Scientific Research, the university has developed into a dynamic institution that combines academic excellence, innovation, and community engagement. For more than three decades, the University of AlMaarif has been committed to preparing highly qualified graduates capable of meeting the demands of local and international labor markets.Situated in western Iraq, the University of AlMaarif offers students a modern educational environment that emphasizes both theoretical knowledge and practical skills. The university has earned a strong academic reputation through its continuous efforts to enhance educational quality, promote scientific research, and establish meaningful collaborations with national and international institutions. Its strategic vision focuses on empowering students with the competencies needed to contribute effectively to sustainable development and technological advancement.The University of AlMaarif offers a diverse range of undergraduate and postgraduate programs across multiple disciplines, including medical and health sciences, engineering, information technology, management sciences, humanities, and physical education. Its academic programs are designed according to contemporary educational standards and are regularly updated to address emerging scientific and technological developments.Research and innovation represent core pillars of the University's mission. Faculty members actively contribute to scientific publications, academic conferences, and collaborative research projects that address societal and industrial challenges. The University continuously invests in modern laboratories, digital learning technologies, and advanced educational infrastructure to provide students with a comprehensive and engaging learning experience.Beyond academic excellence, the University of AlMaarif maintains a strong commitment to community service. Through scientific seminars, workshops, professional training programs, and volunteer initiatives, the University plays an important role in supporting social development within Al Anbar Governorate and across Iraq. Its graduates have contributed successfully to various sectors, reflecting the University's dedication to producing skilled professionals and responsible leaders.Today, the University of AlMaarif continues to strengthen its position among Iraq's leading higher education institutions by fostering innovation, academic integrity, and international cooperation. With its student-centered approach and forward-looking vision, the University remains committed to shaping future generations of scholars, researchers, and professionals who will contribute positively to both Iraqi society and the global community. University of AlMaarif Iraq

That is the nice tips and hints certainly towards some of those having their first go blogosphere, temporary not to mention adequate information… Thanks a lot for the purpose of showing gas 4 free :. Vital read through piece of writing. borneo cruise

This is the details My business is locating everywhere you go. Appreciate it on your blog site, I just now signed up your site. That is a pleasant blog site. inch. vw108 slot

This is the details My business is locating everywhere you go. Appreciate it on your blog site, I just now signed up your site. That is a pleasant blog site. inch. qris108 slot

Growth often begins when we're willing to step outside our comfort zone and communicate openly. Meowdoku is one of my favorite ways to recharge between busy workdays.

MB&F Watch Guide: Independent Avant-Garde Horology, Legacy Machine Collection & Three-Dimensional Mechanical Sculptures Limited for Maximilian Büsser and Friends, MB&F replica watches can be a legendary independent Geneva watch studio founded in 2005, completely different from mainstream business oriented watch brands. Instead of building timepieces that merely notify time, MB&F positions each product as a mechanical machine worn within the wrist , cooperating using top independent watchmakers, manuacturers and decorators to build sculptural, three-dimensional horological art bits that subvert traditional level dial design logic. The brand’s almost all representative work is the Legacy Machine (LM) family , with the hanging floating balance wheel becasue it is universal signature visual draw. The classic LM101 uses a dial layout to fully disclose the beating balance tire as the core visual target, matched with split sub-dials for hour/minute display along with power reserve indication. Later enhanced models such as LM Divide Escapement EVO adopt class 5 titanium cases, 72-hour dual-barrel power reserve, 80-meter water proof and integrated rubber ties, adding practical wearability for you to artistic design without sacrificing typically the brand’s surreal mechanical appearances. Higher-end releases including LM Thunderdome equip the planets fastest triple-axis tourbillon technique, while LM Perpetual does apply a patented mechanical model to optimize perpetual date operation, winning multiple GPHG prestigious replica swiss honors. Every MB&F movement is fully custom-developed and hand-finished, with anglage, perlage and hand-blued anchoring screws completed by top-tier builders. Most models adopt constrained numbered small-batch production, generating each Legacy Machine element scarce collectibles in the 3rd party watch market. Unlike mass-produced robust instrument watches from replica tudor watches or commercial ultra-luxury game chronographs like AP Royal Oak Offshore, MB&F objectives seasoned collectors who practice horological creativity and imaginative expression rather than pure donning functionality. The bold split mechanical structure and domed sapphire crystal viewing screen turn ordinary wrist-wearing in a visual feast of transferring machinery. Financial institution Value of MB&F Timepieces MB&F fake luxury watches are not daily accessories for some users, but curated kinetic art collections. Thanks to very low output volume and distinctive cooperative movement technology, well-preserved Legacy Machine series keep strong appreciation performance around the secondary market. For hobbyists tired of homogenized mainstream luxury watches, MB&F represents by far the most distinctive creative side of recent Swiss haute horlogerie. replica audemars piguet Royal Oak Offshore Bomberg BB-68 replica watches

Typically the Anatomy of Thin: Deconstructing the Record-Breaking Richard Mille RM UP-01 Ferrari In the pantheon of Richard Mille, a brand synonymous along with ergonomic tonneau cases along with extreme mechanical resilience, typically the RM UP-01 Ferrari reaches its destination as a shock to the system-or rather, a shockingly thin a single. This collaborative masterpiece together with Ferrari represents a complete philosophical departure, trading the brand's typical three-dimensional depth for the flattened, pavement-hugging profile in which redefines the very concept of some sort of sports watch. It is not a evolution of an existing assortment but a year-zero wave, built from the ground up to beat a single, obsessive goal: to get one of the flattest mechanical wrist watches on the planet. high quality fake watches richard mille RM UP-01 Ferrari replica concord saratoga watches The genius of the RM UP-01 Ferrari lies not throughout stripping down a activity but in recalibrating the entire executive philosophy of the watch. Eschewing the traditional stacked movement structure, the engineers merged often the movement with the case, making use of the baseplate as the chassis on its own. This allowed for a staggering all round thickness of just 1 . 75 millimeters. The face, a tiny offset disc offering the hours and short minutes, is not a protective cover but the integrated functional layer. Your entire package weighs under 30th grams, yet it happily wears the Prancing Pony and withstands accelerations involving over 5, 000 g's. Our article on the Richard Mille RM UP-01 Ferrari ultra-thin watch engineering uses a microscopic look at how this kind of titanium marvel achieves this sort of structural rigidity without a classic mainplate. Donning the RM UP-01 can be a surreal experience. It doesn't feel as if a conventional watch; it feels such as a second skin or a item of high-tech automotive equipment in a tight to your wrist. The purpose selector and winding crown teeth are integrated flush while using bezel's flat plane, necessitating a tactile, deliberate connection that makes setting the time think that an event. This is not a wristwatch for introverts; its wafer-thin silhouette and technical, virtually brutalist, exposed gear educate demand conversation. For a entire sensory breakdown of this exclusive user experience, we've gathered an extensive Richard Mille RM UP-01 Ferrari review in addition to wrist experience, detailing precisely how this engineering disruptor works with into daily life. Ultimately, the RM UP-01 Ferrari is a real manifestation of collaborative R& D, translating Ferrari's cosmetic codes-the Giallo Modena decorations, the sculptural lines on the SF90 Stradale-into a horological laboratory on the wrist. It is just a statement that haute horology's future isn't just in putting complications, but in mastering the actual physics of space as well as material. This watch it not just a purchase; it's an purchase of a piece of contemporary micro-mechanical art work. For those seeking guidance on coming into this rarefied world of acquiring, our Richard Mille ultra-thin watch buying guide presents essential advice on exclusivity, availableness, and what sets these best creations apart. Audemars Piguet Royal Oak Offshore replica replica Jacob and Co. Casino luxury fake watches fashion replica watches fake watches for sale replica jacob and co Astronomia watches

When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Dewabet Sbobet When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Airasiabet Sports When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Situs Domino88 When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Vegas88 Roulette When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Citislots Togel When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Ilucky88 Mahjong Wins 3

A new study found that adding hemp oil or hempseed byproduct to dog food can improve digestive health without negatively impacting the overall microbial system. The study, published in the journal Veterinary Sciences, suggests that certain types of hemp derivatives could be safely incorporated into canine food as ingredients. However, the effects appear to be partly dependent on whether the cannabis is added as an oil or fiber supplement. For the study, researchers at Kasetsart University in Thailand put 24 mixed-breed dogs into three groups: One had food containing an 11 percent concentration of a fiber-rich hempseed byproduct, another received food with 2 percent hempseed oil and a third got a control diet with no hemp. The dogs were fed the diets for 90 days. Researchers compared fecal samples from before the experiment with those from after 30 and 90 days. Genetic sequencing was used to track changes in the composition and diversity of intestinal bacteria. Dogs that were fed a diet with hempseed oil-infused food showed a larger increase in microbial species richness. “Hempseed fractions modulate the canine microbiome in a formulation-specific manner without disrupting ecological stability, supporting beneficial health effects in canine nutrition.” The diet was also associated with increased levels of “beneficial” bacteria from the Lactobacillaceae family, whereas the fiber-rich hempseed byproduct was linked with Actinobacteriota. “Hempseed derivatives altered microbial composition by promoting certain beneficial bacteria, supporting canine gut health in a formulation-dependent manner,” the authors wrote, adding that the results “provide evidence for their safe inclusion as functional ingredients in dog food.” Despite the differences between the diets, a key collection of 19 bacteria were present throughout the study. And by day 90, the microbial composition also seemed to stabilize, indicating the dietary supplements did not significantly disrupt the dogs’ intestinal systems. Overall, the findings suggest that hempseed ingredients can be safely integrated into dog food while supporting gut health by promoting certain beneficial bacteria, the study authors said. This is one of the latest studies into cannabis and its potential impacts on dogs. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — For example, a recent systemic review of scientific literature determined that studies “consistently show” that CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans. The National Animal Supplement Council (NASC) promoted a study in 2024 that it said shows CBD is “safe for long-term use” in dogs—a significant finding given emerging research that cannabis can effectively treat conditions such as anxiety and certain skin diseases among canines. Another 2024 case study found that cannabis appears to be a “viable alternative” treatment option for dogs suffering from a common skin disease, especially if they experience adverse side effects from conventional steroid therapies. Meanwhile, prior research suggests that giving dogs a dose of CBD could help counteract the ill effects of accidental THC consumption, according to a study that authors called “the first report of treatment of canine THC toxicosis by administration of CBD.” Another study that was published in 2024 found that dogs that receive daily doses of CBD see “significant reductions” in stress and anxiety related to car travel. Other research has demonstrated benefits of CBD such as reduced frequency of seizures among dogs who receive the cannabinoid. Also, a study published in 2018 found that dogs with arthritis see improvements with CBD treatment. When it comes to other animals, the U.S. Department of Agriculture (USDA) found in 2013 that cows that are fed hempseed cake retain very low concentrations of THC and CBD in their bodies, indicating that meat products from hemp-fed cattle are safe for human consumption. Another federally funded study published in 2022 found that feeding cows hemp reduces their stress. Researchers have also looked into how CBD affects stress and pain in horses. The post Adding Hemp To Dog Food Improves Digestive Health, New Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The Cannabis Act, as revised, removed the language this court concluded violated the U.S. Constitution’s Dormant Commerce Clause.” By Christopher Shea, Rhode Island Current A court order that blocked state regulators from awarding cannabis retail licenses may come to an end soon, a Rhode Island federal judge indicated Wednesday. U.S. District Judge Melissa DuBose wrote in an order that she would dissolve the preliminary injunction she issued April 8 now that the Rhode Island Cannabis Act no longer requires all retail license holders to be majority-owned by Rhode Island residents. “The Cannabis Act, as revised, removed the language this court concluded violated the U.S. Constitution’s Dormant Commerce Clause,” she wrote. But that outcome hinges on the 1st U.S. Circuit Court of Appeals in Boston sending the lawsuits over Rhode Island’s former residency requirement for recreational cannabis licenses back to DuBose’s Providence courtroom. Tim Rondeau, a spokesperson for the Rhode Island Office of Attorney General, said Thursday that state attorneys have requested a stay in all appellate proceedings in order for the District Court to issue an indicative ruling. Twenty recreational cannabis retail licenses have remained on hold since DuBose’s April 8 ruling, leaving about 100 applicants in limbo—many of whom have continued paying rent on storefronts they still cannot open. The Cannabis Control Commission appealed DuBose’s injunction on April 14. But after Gov. Dan McKee (D) signed a pair of bills repealing the challenged residency requirement, lawyers from the Attorney General’s Office representing the state filed a motion to dissolve DuBose’s preliminary injunction arguing it was now moot. The legal challenges began in May 2024, when California cannabis entrepreneur Justyna Jensen sued the Cannabis Control Commission in U.S. District Court in Providence, arguing Rhode Island’s residency requirement for licenses under the state’s 2022 Cannabis Act violated interstate commerce protection. Under the new law, applicants are defined as a person or a business who has “made an application for issuance of a license or certificate to own or engage in a cannabis business.” The legislation also removes any Rhode Island references in the eligibility criteria for applying for one of six social equity licenses, which are reserved for those adversely affected by the war on drugs. Those businesses must still be majority owned by one or more people who can show they were disproportionally impacted by criminal enforcement of past prohibitions, including being arrested or having a family member who was. Charon Rose, a spokesperson for the Cannabis Control Commission, said in a text message that staff for the regulatory panel will provide an update on the case when it meets at 1 p.m. Friday. The agenda also includes next steps the commission will take in the licensing process, including refunds for any voided applications from the state’s first go-around. This story was first published by Rhode Island Current. The post Federal Judge Signals Rhode Island Officials Will Soon Be Able To Award New Marijuana Business Licenses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Former U.S. transportation secretary and potential 2028 presidential candidate Pete Buttigieg says that the medical benefits of marijuana have “made a difference” for people close to him. “I can tell you that I think the American majority recognizes that people should have access to this,” the former Biden administration cabinet member and South Bend, Indiana mayor said during a visit to Nebraska last week to support a Democratic congressional candidate from the state. “Its certainly made a difference to people I’ve served with, to people in my extended family, and I hope common sense prevails,” Buttigieg said. The comments come as Nebraska officials are moving forward to some extent to implement ballot initiatives that voters approved in 2024 to legalize medical cannabis and provide for a regulatory structure to oversee businesses that provide it to patients. Nebraska Attorney General Mike Hilgers (R) has claimed that the cannabis measure never should have appeared on the ballot due to alleged issues related to the petitioning campaign in support of it. Advocates in the state have also complained that rules approved by regulators and signed by Gov. Jim Pillen (R) have rolled back the scope of patient rights contemplated in the initiatives that voters passed. “It is heartbreaking to watch Pillen, to watch AG Hilgers and to watch the legislature try to strip away access to something that the vast majority of voters in this state have said that they want,” Democratic congressional candidate Denise Powell said alongside Buttigieg last week. “So it’s heartbreaking. I think our folks here deserve better and I hope that eventually people will do the right thing here by the voters,” Buttigieg, for his part, endorsed marijuana legalization and broad drug decriminalization during his unsuccessful 2020 run for the Democratic presidential nomination. In 2019, his campaign released a racial justice plan that included policies to legalize cannabis and remove criminal penalties for possession of all drugs. “We will, on the federal level, eliminate incarceration for drug possession, reduce sentences for other drug offenses and apply these reductions retroactively, legalize marijuana and expunge past convictions,” the plan said. In a separate plan aimed at addressing mental health issues in the country, the candidate explicitly said he would pursue “decriminalizing all drug possession” during his first term in office if elected. Buttigieg talked about his drug reform agenda during a visit to a dispensary in Las Vegas in October 2019, which Marijuana Moment attended. During that trip, the former mayor told Marijuana Moment that doctors at the U.S. Department of Veterans Affairs (VA) should be able to recommend medical cannabis to military veterans. He also said that “legitimate medical use of cannabis should be covered” by health insurance. He later when on to serve as head of the Department of Transportation (DOT) under President Joe Biden, telling a congressional committee in 2024 that moving cannabis to Schedule III of the federal Controlled Substances Act wouldn’t affect drug testing policies for commercial truckers, noting the department specifically lists marijuana as substance to screen for. The post Medical Marijuana Has ‘Made A Difference’ For Pete Buttigieg’s Family And For Veterans He Served With In The Military, He Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A new law in Georgia that has expanded access to medical marijuana is enticing a lot more patients to apply for the state’s program. The legislation, which Gov. Brian Kemp (R) signed in May and which officially took effect on July 1, adds new qualifying conditions for the program, allows patients to vaporize medical cannabis and changes THC potency limits, among other reforms. Since the start of June, the number of registered medical marijuana patients has grown nearly 22 percent, according to data from the Georgia Department of Public Health that was obtained by WXIA-TV. The outlet reported that whereas there were about 34,000 active patients in the program at the beginning of last month, that number has now grown to more than 41,400. Since the beginning of July, when there were 36,703 active patients, the program has grown by almost 13 percent just over the last few weeks. Judson Hill, president of medical marijuana company Fine Fettle, told WXIA that “July 1st was by far our busiest day. We had folks lined up an hour before we opened our doors.” “These inhalable products allow them to have that relief immediately, where an oil-based product has to go through your digestive system, which could take 30 minutes to an hour to kick in, so it really was just not as helpful as they needed,” he said. Gary Long, the CEO of Botanical Sciences, a Georgia-based medical cannabis company, recently predicted that the expanded law could triple the number of patients by mid-2027. Under the legislation, patients with lupus are allowed to legally access medical marijuana, building on the state’s prior law that allowed certain people with cancer, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, ALS, autism spectrum disorder, intractable pain and other conditions to qualify. The policy, which was sponsored in the legislature by Sen. Matt Brass (R), also removes the requirement for many conditions that the patient’s status be severe or end-stage to be allowed to enter the medical cannabis program. The reform also expands how patients can use medical marijuana. Previously they were able to access oils, tinctures, capsules, lozenges, topicals and transdermal patches—but now vaping is allowed as delivery method for people over 21 years of age, though smoking continues to be prohibited for all patients. The Putting Georgia’s Patients First Act additionally replaces the current 5 percent THC potency cap for medical cannabis products with a limit of 12,000 milligrams of THC that a patient can possess at any one time. “These changes, while meaningful to the affected patients, do not materially alter where Georgia sits in the national landscape on this issue,” Kemp said in a signing statement last month. “This bill passed with a constitutional majority in both chambers of the General Assembly.” “I, like many of those who expressed opposition to this bill, have reservations about the legalization of recreational cannabis. Many states that have legalized recreational cannabis have come to regret that decision,” he said. “I also recognize that for some patients, medical cannabis provides significant relief to symptoms that would otherwise go untreated or would be treated with even more harmful opioids.” “I do not believe that a well-implemented medical cannabis program must inevitably lead to the legalization of recreational use in Georgia, nor is the question of recreational use anywhere in the bill on my desk for signature,” the governor said. The new law also replaces references to “low THC oil” in current law with “medical cannabis.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The Georgia Access to Medical Cannabis Commission, which oversees the program, also now has a new duty of conducting public awareness activities about “effective uses of medical cannabis and products, including, but not limited to, publishing materials and conducting outreach and public education activities to inform members of the public, law enforcement, and healthcare providers about the medical cannabis program in this state and the potential benefits that medical cannabis and products may have to eligible patients.” Last year, House leaders created a Blue-Ribbon Study Committee on Georgia’s Medical Marijuana and Hemp Policies to examine the state’s cannabis laws. Lawmakers in Georgia have also considered legislation to support research on the therapeutic benefits of psychedelics. The post Georgia’s Expanded Medical Marijuana Law Generates Huge Boost In Number Of Registered Patients appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. slot online When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Bola88 Resmi When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Dominoqq When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Nagapoker link When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Parlay Bola When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Bolagila Resmi When you use a genuine service, you will be able to provide instructions, share materials and choose the formatting style. Dewavegas Livecasino

NDAA psychedelic amendments pass; CA treasurer’s marijuana banking hearing; Alcohol lobby questions cannabis drink tax; Study: CBD for cancer symptoms Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW A press release from the office of Rep. Andy Barr (R-KY) claims the White House supports his new bill to keep hemp THC products legal—but while President Donald Trump does want to reverse the impending broad federal recriminalization of hemp, an administration official declined to back the specific legislation. Sources told Marijuana Moment that the White House takes issue with the Barr bill’s provisions on inhalable hemp products. The House of Representatives passed National Defense Authorization Act amendments to extend a military psychedelics research program for an additional six years and to codify provision of a psychedelics executive order signed by President Donald Trump—but separate proposals on marijuana test waivers for recruits and access to Schedule I drugs under “Right to Try” were blocked from receiving votes. California Treasurer Fiona Ma (D) announced she will be convening a hearing on marijuana businesses’ banking access issues next week. The Wine & Spirits Wholesalers of America is backing a new bill in Congress to keep hemp THC products legal, saying cannabis drinks “should be treated like beverage alcohol”—but arguing that the legislation’s tax provisions need “continued discussion.” A new study of cancer survivors found that “about a fifth used CBD, primarily for symptom relief of distress (stress, anxiety, or depression), sleep, pain, and neuropathy, and more than half of survivors reported at least some benefit for each concern.” / FEDERAL The Congressional Research Service noted circuit appeals court spits on marijuana consumers’ gun rights in a report. / STATES Nebraska Democratic gubernatorial candidate Lynne Walz, a former state senator, pledged to issue an executive order on medical cannabis if elected. New York medical cannabis rules changes took effect. Missouri regulators are waiving a requirement for marijuana business employees to have a government-issued photo ID on their person at all times. Minnesota’s top cannabis regulator said the Trump administration has not provided guidance to states on how it will interpret or enforce the federal recriminalization of hemp THC products that is set to take effect in November. Michigan regulators filed a complaint against a marijuana business over alleged violations. Vermont regulators are hosting a variety of cannabis workgroup meetings over the next several weeks. California regulators sent updates about various cannabis issues. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL The Saint Kitts and Nevis government hired a consultant to shape banking rules for medical cannabis businesses. / SCIENCE & HEALTH A review concluded that “cannabinoids are a promising but emerging treatment option of neuropathic pain.” A review concluded that “current evidence does not consistently support global neurodevelopmental impairment following prenatal cannabis exposure but suggests a pattern of selective vulnerability in behavioural, attention and executive regulatory domains.” / BUSINESS FLUENT Corp. is selling its New York licenses. / CULTURE Lollapalooza named Señorita as its official THC beverage. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Does White House actually support new hemp bill? (Newsletter: July 24, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Generator teks kosong ( blank text ) online. Dapatkan teks kosong dengan mudah untuk semua keperluan Anda.

The state treasurer of California has announced she will be convening a hearing next week to highlight the marijuana industry’s banking access “challenges” and the effect it has on businesses, workers and communities. The hearing, hosted by Treasurer Fiona Ma (D), comes ten years after a predecessor of hers in the role launched a Cannabis Banking Working Group to examine the issue. Titled, “Continuing the Conversation: Advancing Safe and Legal Banking for California’s Cannabis Industry,” the hearing on Wednesday will feature state and local officials, financial institutions and marijuana business representatives. The intent is to “review the progress made, discuss remaining barriers and consider practical steps California can take to support a safe, transparent and well-regulated legal cannabis market,” a press release from Ma’s office said. “Nearly a decade after the launch of the Cannabis Banking Working Group, California’s legal cannabis industry continues to face barriers to accessing affordable and reliable financial services because of the ongoing conflict between state and federal law,” Ma said. “This hearing will help us assess what has changed, identify the challenges that remain and continue the conversation about practical solutions that support public safety, transparency and responsible business operations.” Last month, bipartisan U.S. House and Senate members refiled legislation to protect banks from being punished for providing financial services to marijuana businesses. Earlier iterations of the banking legislation have been introduced in past sessions of Congress, and while versions have been approved by the House of Representatives on several occasions, the reform has never been enacted into law. While some banks do serve marijuana businesses, the plant’s ongoing federal illegality has made many reluctant to work with the industry. “Restricted access can increase operating costs, complicate routine financial transactions and require some businesses to handle larger amounts of cash, creating additional security and administrative concerns,” Ma’s office said. The post California Treasurer Announces Hearing On Marijuana Business Banking Access Issues appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The office of a Republican congressman who filed a new bipartisan bill to keep certain hemp-derived THC products federally legal this week sent a press release saying the legislation is “backed by the White House”—but an administration official deflected Marijuana Moment’s question about the matter and other sources say President Donald Trump’s team has problems with specific provisions of the proposal. Rep. Andy Barr’s (R-KY) press release about the measure—which would put in place a number of regulations for manufacturing, labeling, sales and taxation of hemp-derived products, including an age limit of 21—contains the subheadline, “Barr’s Bipartisan Bill is Backed by the White House and the lead Democrat on the House Agriculture Committee,” referring to Rep. Angie Craig (D-MN), who is cosponsoring it with him. But while the Trump administration and the president himself have repeatedly called on Congress to pause or reverse the impending federal recriminalization of hemp THC products that is set to take effect later this year, the White House has not specifically endorsed the new 60-page bill. A White House official, when asked by Marijuana Moment on Wednesday about whether the administration supports the legislation, replied more generally, saying in an email that “the only definitive positions that the White House has taken on this issue are in the [sic] President Trump’s December EO and April Truth post,” referring to a marijuana rescheduling executive order that also addressed hemp issues. When pressed about whether the administration plans to endorse the Barr bill specifically, the official did not reply. Two sources familiar with negotiations around the legislation told Marijuana Moment on Thursday that the White House takes particular issue with provisions of the legislation that include inhalable forms of cannabis in the definition of legal hemp-derived cannabinoid products. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that Trump signed during his first term in office. But late last year, the president signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. When asked about the administration’s unclear stance on the legislation despite the claim in the congressman’s press release, his office pointed Marijuana Moment to a previously released statement from the White House Office of Management and Budget and a letter that aides to the president sent to Barr earlier this year. In April, White House officials provided Barr with feedback on draft legislation to create a regulatory framework for hemp, writing in a letter that they “appreciate your work to advance the policy of” the marijuana executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, wrote to the congressman. “We are available for discussion and further technical assistance.” Also in April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Industry advocates say that the law as enacted last year not only threatens to prohibit intoxicating and synthetic cannabinoid products but also stands to remove popular full-spectrum CBD products that many Americans use therapeutically from the market. “ONE in FIVE adults used it in the past year, and many say it improved their chronic pain enormously,” the president said in his social media post, adding that hemp-derived CBD “has made a HUGE difference for so many people.” He also referenced a new initiative the administration launched in April to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows products to have up to 3 milligrams of total THC per serving. A federal judge granted the government’s motion to dismiss marijuana legalization opponents’ lawsuit challenging the initiative, but that is being appealed. “In December, I signed a very important Executive Order calling for Research and Innovation for Hemp-derived CBD,” Trump said. “Our wonderful Dr. Mehmet Oz moved fast to follow the directive in the Executive Order, and launched a model for some Seniors earlier this month. But more must be done!” “Please get it done, and SOON,” the president said in reference to a congressional fix for the broad recriminalization set to take effect in November. “Thank you for your attention to this matter!” The cannabis rescheduling executive order that Trump signed in December and that the White House official referenced in the email to Marijuana Moment this week said: “The Assistant to the President and Deputy Chief of Staff for Legislative, Political, and Public Affairs shall work with the Congress to update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks. This will include consultation with appropriate executive departments and agencies and authorities to develop a regulatory framework for hemp-derived cannabinoid products, including development of guidance on an upper limit on milligrams of THC per serving with considerations on per container limits and CBD to THC ratio requirements.” More recently, in a letter to House Speaker Mike Johnson (R-LA) last month, OMB Director Russell Vought said the Trump administration wants lawmakers to “ensure the fair treatment of hemp products”—specifically citing an earlier amendment that Barr filed to keep many hemp products legal while adding regulations and taxes. While that amendment also included inhalables, several of its provisions are significantly different from the new bill that Barr filed this week and that the congressman’s office said the White House supports. The subheadline about White House support for the bill was included in Barr’s press release as emailed to reporters, but does not appear in the version that is on his congressional website. It’s ultimately not clear how far Trump wants to scale back the scope of the scheduled federal restrictions on hemp products and what kinds of revised THC rules and limitations he would prefer to sign into law. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” OMB separately said last month, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” Meanwhile, hemp policy observers expect to see a Senate companion bill to Barr’s proposal filed as soon as next week, likely from Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN). It is expected that the legislation will not be identical to the House version and could potentially contain changes intended to address the White House’s concerns. Sheehy recently cited hemp legislation as an area where Republicans and Democrats can work together in an otherwise “hyperpartisan time.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The Wine & Spirits Wholesalers of America (WSWA), an alcohol industry trade association issued praised for Barr’s hemp bill this week, but said the measure’s tax provisions require “continued discussion.” Barr spoke at a meeting with hemp industry operators earlier this year and previewed the legislation—saying it faces opposition from a coalition of strange bedfellows including sectors of the alcohol industry, marijuana businesses and cannabis legalization opponents. Sen. Ted Cruz (R-TX) predicted that it will be an “uphill path” to avert the scheduled federal recriminalization of hemp THC products this year. The National Restaurant Association recently sent a letter urging congressional leaders to delay the federal recriminalization of hemp THC beverages and replace it with a regulatory framework that “ensures consumer safety while meeting growing market demand” for the products as an alternative to alcohol. Major retailer Target, meanwhile, recently moved to expand its sales of hemp THC drinks into more states. The post GOP Lawmaker Claims White House Backs His Hemp Bill, But Administration Has Problems With Inhalable Product Provisions, Sources Say appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Nearly one in five cancer survivors say they’ve used the cannabis component CBD after getting their diagnosis—primarily to manage pain, sleep difficulties and emotional distress, according to a new study. And more than half of those who used it for specific symptoms reported at least some benefit. The research, published in the Journal of Palliative Medicine, surveyed 1,258 survivors of nine different types of cancer. Among those participants, 226—or 18 percent—reported using CBD after being diagnosed. Researchers with Memorial Sloan Kettering Cancer Center, the University of Texas Anderson Cancer Center and Mount Sinai Hospital additionally found that 9 in 10 people who use CBD said they consumed the non-intoxicating cannabinoid for symptom relief. Pain was the most common symptom people said they used CBD to treat (55 percent), followed by difficulty sleeping at 47 percent, stress, anxiety or depression at 35 percent and neuropathy at 18 percent. “Most survivors who used CBD for symptom relief reported improvement.” For each of the symptoms, more than half of participants reported at least some improvement after using CBD. That ranged from 60 percent among those treating neuropathy to 85 percent among the smaller group who used CBD for low energy or fatigue. “About a fifth used CBD,” the authors wrote, “primarily for symptom relief of distress (stress, anxiety, or depression), sleep, pain, and neuropathy, and more than half of survivors reported at least some benefit for each concern.” By contrast, almost half of people who had used the cannabinoid said they eventually stopped, with the most common explanation being that it did not help them. Researchers said clinical trials are needed to better assess the safety and efficacy of CBD for specific symptoms experienced by cancer survivors. Younger cancer survivors and people with brain or gastrointestinal cancers were more likely to report CBD use in initial analyses, the study found. The research adds to a growing body of evidence showing that cancer patients and survivors are using cannabis to manage symptoms. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — For example, another recent study determined that medical marijuana extracts “meaningfully” improve cancer-related symptoms such as sleep difficulties and anxiety—though responses varied among patients depending on personal preferences for individual cannabinoid content of the extracts. Researchers separately found that components of marijuana show “consistent and statistically significant anti-tumor effects” in certain types of cancer, including glioblastoma and breast cancer. The study also showed that cannabinoids seem to “enhance chemotherapy efficacy.” Another systemic review concluded that studies “consistently show” that the CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans. A similar analysis showed that CBD “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties. Scientists explored CBD’s effect on many types of cancer—including some of the most aggressive ones, such as glioblastoma, which affects the brain. They also noted it can help suppressing the growth and metastasis of other cancers, including breast, lung, colorectal, ovarian and prostate, among others. In 2025, a paper published in the journal Pharmacology & Therapeutics, assessed a range of clinical and preclinical findings that the efficacy of chemotherapy drugs can be enhanced by medical marijuana. In a sign of greater acceptance of medical applications of cannabis, President Donald Trump’s choice to serve as the next White House drug czar has called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t object to legalization, even if she might not personally agree with the policy. Also last year, a study found that “patients with cancer using cannabis report significant improvements in cancer-related symptoms.” Photo courtesy of Chris Wallis // Side Pocket Images. The post 1 In 5 Cancer Survivors Use CBD To Treat Symptoms Like Pain, Sleep Problems And Distress, Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

An alcohol industry trade association is endorsing a newly filed bill in Congress that would allow continued sales of certain hemp-derived THC products, partially scaling back a broad ban that is scheduled to take effect later this year. The group, however, says that the measure’s tax provisions require “continued discussion.” The Wine & Spirits Wholesalers of America (WSWA) is particularly applauding the legislation’s provisions that would created a three-tier framework for sales of cannabis-infused beverages, modeled on the system that is currently in place for alcohol. The new Lawful Hemp Protection Act, introduced by Reps. Andy Barr (R-KY) and Angie Craig (D-MN), would put in place a number of regulations for manufacturing, labeling, sales and taxation of hemp-derived products, including an age limit of 21, which WSWA says “moves the marketplace away from uncertainty and toward clear, enforceable rules that protect consumers, support compliant businesses and preserve state regulatory authority.” Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12—though he has since called on Congress to scale back the scope of the forthcoming restrictions. The new 60-page bill, which a press release from Barr’s office says is supported by the White House, would keep many hemp products that are now on the market legal for people over the age of 21, again changing the definition of hemp to allow concentrations of up to 1 percent total THC on a dry-weight basis. “This legislation takes an important step by recognizing that hemp-derived beverages can be regulated using the principles of the three-tier system that has governed beverage alcohol safely and successfully for more than 90 years,” Dawson Hobbs, WSWA’s executive vice president of federal affairs, said in a press release. “WSWA commends the bill’s distinct treatment of hemp beverages as a unique category with an established regulatory model,” he said. “By subjecting these beverages to federal licensing, labeling standards, mandatory age verification, independent testing, excise taxation and state regulatory authority similar to beverage alcohol, Congress can protect consumers and communities.” The proposal as introduced would set a tax on hemp beverages of 5 cents per milligram of THC in addition to a tax on hemp product manufacturers in the amount of 5 percent of their annual sales revenue—a provision that WSWA isn’t exactly endorsing. The group “looks forward to continued discussion about a tax rate that promotes parity with beverage alcohol and supports effective oversight,” it said. “We don’t need to reinvent the wheel,” Hobbs said. “The beverage alcohol model has worked for more than 90 years. These beverages are intoxicating products and should be treated like beverage alcohol.” Under the legislation, there would be a three-tier system for hemp-derived beverages, separated into manufacturers, wholesalers and retailers. No entity could hold a direct or indirect interest in more than one tier—a separation the legislation says will be “strictly maintained.” Among other provisions, the new legislation would also direct federal officials to set potency limits for hemp products and prohibit synthetically produced cannabinoids. It would additionally require that hemp cannabinoid products introduced into interstate commerce would need to be derived exclusively from hemp cultivated, processed, finished, packaged and labeled within the U.S. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In May, WSWA criticized the House of Representatives for passing an updated Farm Bill without including provisions to prevent the federal recriminalization of hemp THC products, saying it represents a “missed opportunity.” Earlier this year, WSWA launched a campaign pushing Congress to call off the scheduled ban on hemp THC beverages and instead regulate the products for consumer access. The efforts includes an educational microsite on the issue that offers resources on the issue and argues that “the same regulatory system that has worked for alcohol should be applied to intoxicating hemp products.” In an op-ed for Marijuana Moment last year, WSWA’s president and CEO argued that regulation of hemp products is superior to prohibition. A separate newly launched group, the Beverage Alcohol Merchants Coalition (BAMCO), is also pushing for a delay in the federal recriminalization of hemp THC products. Its founding members include Total Wine & More, BevMo! by Gopuff, ABC Fine Wine & Spirits, Spec’s Wine and Spirits & Finer Foods, as well as a group of hemp product wholesalers. Barr, the sponsor of the newly filed hemp regulation bill, spoke at a meeting with hemp industry operators earlier this year and previewed the legislation—saying it faces opposition from a coalition of strange bedfellows including sectors of the alcohol industry, marijuana businesses and cannabis legalization opponents. Trump and White House officials have in recent weeks repeatedly called on Congress to delay, alter or reverse the ban. In a letter to House Speaker Mike Johnson (R-LA) last month, for example, White House Office of Management and Budget (OMB) Director Russell Vought said the Trump administration wants lawmakers to “ensure the fair treatment of hemp products”—specifically citing Barr’s earlier amendment to keep many hemp products legal while adding regulations and taxes. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” OMB separately said last month, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. Sen. Tim Sheehy (R-MT) recently cited hemp legislation as an area where Republicans and Democrats can work together in an otherwise “hyperpartisan time.” Sen. Ted Cruz (R-TX), however, predicted that it will be an “uphill path” to avert the scheduled federal recriminalization of hemp THC products this year. The National Restaurant Association recently sent a letter urging congressional leaders to delay the federal recriminalization of hemp THC beverages and replace it with a regulatory framework that “ensures consumer safety while meeting growing market demand” for the products as an alternative to alcohol. Major retailer Target, meanwhile, recently moved to expand its sales of hemp THC drinks into more states. The post Major Alcohol Industry Lobby Backs Bill To Keep Hemp THC Drinks Legal, But It Wants More ‘Discussion’ On Tax Rate appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The U.S. House of Representatives has voted to extend a psychedelics research effort at the Department of Defense (DOD) for an additional six years and to codify provisions of a psychedelics executive order signed by President Donald Trump earlier this year. Meanwhile, Republican leadership in the chamber blocked a separate proposal to expand waivers for military recruits who’ve tested positive for marijuana from even being considered. Lawmakers voted to approve the psychedelics amendments to the National Defense Authorization Act (NDAA) for Fiscal Year 2027 in a voice vote on Wednesday as part of an en bloc package with other unrelated proposals, and the overall bill then passed 216-212. One of the approved measures, sponsored by Reps. Morgan Luttrell (R-TX), Jack Bergman (R-MI), Derrick Van Orden (R-WI), Mike Ezell (R-MS), Troy Carter (D-LA), Morgan McGarvey (D-KY), Lou Correa (DCA), Seth Moulton (D-MA), Sarah Elfreth (D MD) and Michael Rulli (R-OH), seeks to include language in the bill expanding DOD studies on psychedelics that were first authorized under the earlier 2024 NDAA. That program, signed into law by then-President Joe Biden, directed DOD to establish a process by which active duty service members with post-traumatic stress disorder (PTSD) or traumatic brain injury could participate in clinical trials involving psilocybin, MDMA, ibogaine, 5-MeO-DMT and “qualified plant-based alternative therapies.” As enacted, it only required the secretary of defense to issue updated reports on progress within one year of the law passing and then annually for three years after that. The new amendment would replace “three years” in the law with “nine years.” It also specifies that DOD would have to “extend the performance of research conducted using funding awarded under this section to September 30, 2033.” The previously enacted legislation, which was also championed by Luttrell, set aside $10 million to fund the military psychedelic studies. Last month, the House Armed Services Committee approved its version of NDAA and an attached report that calls on military officials to pay greater attention to potential “access pathways” to psychedelic therapies for servicemembers. Citing a psychedelics executive order signed by President Donald Trump in April, the panel urged DOD leaders to “remain informed of lawful research and access pathways relevant to post-traumatic stress disorder and other serious mental health conditions affecting servicemembers during post-deployment and transition periods, and members of the Reserve Components and National Guard who also serve as first responders.” That includes studies on “psilocybin-containing investigational products, including naturally derived whole-mushroom formulations administered in structured therapeutic settings,” the report that the panel approved to be attached to NDAA says. The panel is directing the secretary of defense to issue a report by February 1, 2027 that assesses data on such trials, along with an assessment of “legal and regulatory requirements for expanded access,” including under Trump’s psychedelics executive order as well as a Right to Try law the president signed during his first term in office. The secretary’s report would also need to include a “proposed timeline for potential pilot activities or expanded clinical research beginning in fiscal year 2027, and for any broader implementation thereafter.” The second psychedelics amendment approved on the House floor on Wednesday, sponsored by Luttrell, Correa and Rulli, along with Rep. Michael McCaul (R-TX), would codify info federal law parts of the executive order Trump signed in April. It would require the Department of Veterans Affairs (VA) to designate an official within 90 days of passage to oversee activities related to “emerging therapeutic interventions” such as ibogaine and other psychedelics, and to coordinate with other federal agencies to do so. VA would also be directed to submit a report to Congress within 60 days, and then again every two years, on activities related to “emerging therapeutic interventions, including psychedelic-assisted therapies.” It would separately need to work with the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) to issue a report within 180 days on progress toward implementing Trump’s psychedelics executive order. The amendment also directs the department to create a workforce implementation-readiness plan for psychedelics and other emerging therapeutic interventions. “Every day, our nation loses 17 veterans to suicide,” McCaul said ahead of the vote on Wednesday. “These are men and women who survived combat, but then lost to a quiet and longer war against the invisible wounds that they carried with them.” He spoke about veterans who have had to travel to Mexico to access ibogaine therapy, saying “this needs to be available in the United States of America now in clinical trials for our veterans.” “Countless vets have told me that they were going to give this one shot before they committed suicide,” he said. “They went down, they experienced ibogaine, and they came back cured.” Luttrell said in a press release after the vote that “America’s service members and their families deserve nothing less than our full commitment to their readiness, safety, and quality of life. “This bill delivers on that promise,” he said. “The FY27 NDAA invests in these heroes [and] advances ibogaine and psychedelic-assisted treatment research to battle severe mental health issues… I’m proud of what we secured for our warriors in this year’s bill and look forward to its swift passage in the Senate.” Meanwhile, lawmakers also used last year’s NDAA to push DOD for a “progress report” on the ongoing psychedelic therapy clinical trials. Another proposed amendment to the current NDAA from Reps. Dave Joyce (R-OH) and Dina Titus (D-NV), would have expanded waivers for military recruits who’ve tested positive for marijuana—but the House Rules Committee is not allowing it to advance to a floor vote. The amendment acknowledges that the Army and Navy have already “taken positive steps in their work to design and implement a waiver system that permits potential enlistees into the Armed Forces to reapply for enlistment following a positive toxicology test for tetrahydrocannabinol.” It calls on the Air Force, Space Force and Marine Corps to follow through, especially “given the ongoing recruitment and retention challenges undermining the Armed Forces readiness goals.” A similar measure filed by Joyce and Titus, who are co-chairs of the Congressional Cannabis Caucus, was passed by the House of Representatives last year but was not enacted into law. The current measure would have required those military branches to “develop and implement their own permanent waiver system commensurate with the process employed by the Army and Navy.” It says that the secretary of defense “shall develop a program through which to provide waivers for potential enlistees into the Armed Forces who were not permitted to enlist following a positive toxicology test for tetrahydrocannabinol so that such potential enlistees are permitted to reapply for enlistment.” Further, the Department of Defense would have been required to “assess the feasibility of contacting” prospective enlistees who were previously rejected over cannabis and, “to the extent feasible, develop a plan to contact such potential enlistees.” Within 180 days of enactment, the defense secretary would have needed to submit a report to the congressional committees of jurisdiction with a “plan to create, disseminate, and use a clear definition that highlights that all waivered recruits are qualified and eligible to enlist in the Armed Forces, even if they do not meet every enlistment standard, and that existing standards of enlistment allow for waivers.” In April, the Army enacted a new policy making it so recruits will no longer need to obtain a waiver to enlist if they have a single conviction for possessing marijuana or drug paraphernalia on their records. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Another drug policy amendment to NDAA that was blocked, from Reps. Madeleine Dean (D-PA) and Nancy Mace (R-SC), would have allowed doctors to administer Schedule I drugs such as certain psychedelics to patients with life-threatening conditions by expanding on the country’s “right to try” law. The policy creates an exception within the Controlled Substances Act (CSA) that gives qualified patients access to potential therapies that haven’t yet been approved by FDA. The Dean-Mace proposal is similar to a standalone bill the bipartisan duo filed in Congress late last year. The lawmakers noted when filing the earlier bill that FDA has designated two psychedelics, MDMA and psilocybin, as breakthrough therapies for the treatment of serious mental health conditions. Yet DEA currently has no pathway to authorize physicians to administer the drugs despite the broader right to try policy, they said. To address that, the new legislation would amend current statute to allow DEA to register and authorize doctors to administer the novel therapeutics. In 2024, the House passed a version of NDAA that would have prevented drug testing for marijuana as a condition of enlistment in the military or for commission as an officer. But it was not included in the final version that was signed into law following bicameral negotiations with the Senate. This month, DOD issued a memo to senior Pentagon leadership making clear that marijuana use by military service members and civilian employees of the department remains prohibited, even as the Trump administration is moving to federally reschedule cannabis. Lawmakers have also previously considered NDAA amendments to address restrictive military policies prohibiting service members from using hemp products. In May, the Army published a post reminding soldiers of its “zero-tolerance” policy for all forms of cannabis and its derivatives—including hair care products and lotions made from hemp. Last year, a memo to Air Force personnel in Massachusetts warned that not only marijuana but also hemp-derived cannabinoids, including CBD and delta-8 THC, are prohibited on military bases and related properties. In 2022, the Air Force expressed concern that even using CBD-infused hand sanitizer or hemp granola could inadvertently compromise “military readiness.” DOD more broadly reaffirmed that CBD is off limits to service members in notices published in 2020. The Navy, for its part, issued an initial notice in 2018 informing ranks that they’re barred from using CBD and hemp products no matter their legality. Then in 2020 it released an update explaining why it enacted the rule change. The Coast Guard said that sailors can’t use marijuana or visit state-legal dispensaries. Separately, a general in 2022 said that the Air Force and Space Force were reviewing marijuana policies and considering a “common sense” change that could give potential recruits a pass if they test positive for cannabis. The post House Passes Psychedelics Amendments To Codify Trump Executive Order And Extend Military Research Program Until 2033 appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana & insurance coverage bill filed in Senate; KY medical cannabis in hospitals; Study: Marijuana reduces opioid use Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Reps. Andy Barr (R-KY) and Angie Craig (D-MN) filed a new bill to keep hemp THC products legal and replace the broad ban that’s currently set to take effect in November with a new system of federal regulations and taxes. The White House supports it, a press release from Barr’s office says. Sens. Kevin Cramer (R-ND) and Ruben Gallego (D-AZ) filed a bill to protect insurance companies from being punished for covering marijuana businesses. The Kentucky legislature’s Interim Joint Committee on Health Services held a hearing on a proposal to allow terminally ill patients to use medical cannabis in hospitals—a reform that is being adopted in a growing number of other states. A new study found that “cannabis use for opioid withdrawal was significantly associated with self-reported reductions in opioid use.” “Immediate efforts to improve access to legal cannabis—especially for structurally-marginalized [people who use drugs] at highest risk of overdose—may offer a step towards reducing the health and social harms of opioid use.” The Alabama State Committee of Public Health held a hearing on whether to reschedule marijuana under state law in line with the Trump administration’s federal move—hearing testimony from conservative activists who oppose the reform. / FEDERAL Customs and Border Protection included marijuana in a list of “dangerous narcotics” as part of “drug interdictions that save lives.” The Drug Enforcement Administration Museum posted a video about heroin bottles in its collection from when the drug was used as a cough remedy. Kansas Democratic U.S. Senate candidate Noah Taylor discussed his support for marijuana legalization. / STATES New Hampshire Gov. Kelly Ayotte (R) signed an ibogaine research bill. Kansas Democratic gubernatorial candidates agreed on supporting marijuana legalization during a debate. Arizona regulators announced a recall of marijuana products due to possible contamination with aspergillus. Virginia regulators are facing an expected lawsuit over new hemp product restrictions. Florida regulators withdrew proposed changes to medical cannabis business application rules. Oklahoma regulators published guidance about the medical cannabis recall process. A report from Maryland officials recommends broadening the cannabis-focused Office of Social Equity’s mandate. The Rhode Island Cannabis Control Commission will meet on Friday. The Iowa Medical Cannabidiol Board will meet on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Killeen, Texas City Council received an annual report on enforcement of the voter-approved local marijuana decriminalization law. / SCIENCE & HEALTH A study of people in recovery from substance use disorders found that “all participants believed cannabis was less addictive than alcohol, cigarettes, and cocaine, but Current-[cannabis users] believed cannabis was significantly less addictive than Former- and Never-CU.” A study of cannabis cultivation found that “licensed farms consistently predict lower nearby unlicensed cultivation” and that “bans and enforcement shift cultivation rather than suppress it.” / ADVOCACY, OPINION & ANALYSIS A poll of Nebraska adults found that 47 percent support legalizing recreational and medical marijuana, 37 percent back medical cannabis legalization only and 17 percent don’t want any form of legalization. / BUSINESS Auxly Cannabis Group Inc. announced a 14:1 share consolidation. / CULTURE Bill Maher spoke about how he uses marijuana as part of his creative process. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post White House backs bill to keep hemp THC products legal, GOP sponsor says (Newsletter: July 23, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Many thanks regarding submitting this kind of fantastic write-up! I came across your internet site perfect for my own wants. It includes great and also beneficial content. Maintain the nice perform! ulartoto

This is the details My business is locating everywhere you go. Appreciate it on your blog site, I just now signed up your site. That is a pleasant blog site. inch. toto macau 4d

I had most recently initiated a fabulous web page, the details you will provide you with here comes with really helped others really. Regards just for all of the effort & succeed. slot gacor